Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Gilead Inks Gene Editing Collaboration Deal for HBV Infection
by Zacks Equity Research
Gilead (GILD) enters into a strategic collaboration with Precision BioSciences for developing therapies aimed at eliminating hepatitis B virus by using the latter's gene editing platform ARCUS.
Company News For Sep 13, 2018
by Zacks Equity Research
Companies in the news are: GILD, VZ, BHC and WBC
Gilead's Rheumatoid Arthritis Drug Successful in Phase III
by Zacks Equity Research
Gilead (GILD) and partner Galapagos' rheumatoid arthritis candidate meets all primary and key secondary endpoints in first phase III study.
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
by Zacks Equity Research
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Merck's Antibacterial Drug Succeeds in Label Expansion Study
by Zacks Equity Research
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
Regeneron/Sanofi's sBLA for Praluent to be Reviewed by FDA
by Zacks Equity Research
The FDA will review Regeneron (REGN) and Sanofi's sBLA for its PCSK9 Inhibitor Praluent to reduce risk of major adverse cardiovascular events.
Incyte, Foundation Medicine Partner for Companion Diagnostics
by Zacks Equity Research
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Endocyte Announces FDA's Acceptance of Trial Endpoint Change
by Zacks Equity Research
177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.51, moving +0.36% from the previous trading session.
Shire's ADHD Portfolio Remains Strong Amid Competition
by Zacks Equity Research
Shire (SHPG) has a strong hold in the attention deficit hyperactivity disorder (ADHD) market despite facing competition.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.
Top Research Reports for Abbott, Gilead & FedEx
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Abbott (ABT), Gilead (GILD) and FedEx (FDX).
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy
by Zacks Equity Research
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.
Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint
by Zacks Equity Research
Gilead's (GILD) ankylosing spondylitis candidate, filgotinib meets primary endpoint in phase II study.
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
by Zacks Equity Research
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Horizon Pharma Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.
Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout
by Zacks Equity Research
Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.
MannKind Stock Up on Licensing Deal With United Therapeutics
by Zacks Equity Research
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals
by Zacks Equity Research
Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.
Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)
by Zacks Equity Research
Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.
Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.
AstraZeneca's Lupus Drug Misses Primary Endpoint in Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.